Postinfarction heart failure: surgical and trans-coronary-venous transplantation of autologous myoblasts

Nature Clinical Practice. Cardiovascular Medicine
Tomasz SiminiakMaciej Kurpisz

Abstract

Increasing experimental evidence indicates that skeletal myoblasts can be considered as a possible source of cells for regeneration of contractile performance in chronic postinfarction myocardial injury. In experimental models, the observed functional benefit of transplanting skeletal myoblasts into an area of chronic fibrotic myocardial scar has led to the development of clinical trials to evaluate the potential use of autologous skeletal myoblasts for myocardial regeneration in patients with postinfarction heart failure. We conducted an independent, phase I clinical trial to evaluate myoblast transplantation during coronary artery bypass grafting. In addition, to test whether the effect of transplanted cells on myocardial contractility was independent of revascularization, we performed a clinical study of percutaneous transvenous myoblast transplantation-the POZNAN trial. These trials have shown the feasibility of myoblast transplantation during cardiac surgery and via a percutaneous route, as well as the safety of both procedures when performed with concurrent prophylactic administration of amiodarone. Here, we review the details of our observations from both of these phase I clinical trials in the context of the clinical wo...Continue Reading

References

Sep 1, 1989·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·N B SchillerI Schnittger
Feb 1, 1996·Circulation Research·R K LiM K Mohabeer
Feb 24, 2001·Lancet·P MenaschéJ P Marolleau
Jun 1, 2001·The Annals of Thoracic Surgery·R M El OakleyM H Yacoub
Apr 8, 2003·Journal of the American College of Cardiology·Philippe MenaschéDenis Duboc
Jul 2, 2003·Circulation·Jing ZhangGeorge J Broze
Sep 10, 2003·Circulation·Tomasz Siminiak, Maciej Kurpisz
Jan 27, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Husnain Kh HaiderEugene K W Sim
Dec 24, 2004·Journal of Endovascular Therapy : an Official Journal of the International Society of Endovascular Specialists·Hüseyin InceChristoph A Nienaber

❮ Previous
Next ❯

Citations

Aug 25, 2009·Tissue Engineering. Part B, Reviews·Gordana Vunjak-NovakovicMilica Radisic
Jul 9, 2011·Ageing Research Reviews·Kai Hong WuBin Zhou
Nov 17, 2007·Seminars in Cell & Developmental Biology·Robert Zweigerdt
Jan 30, 2007·Trends in Molecular Medicine·Antonia GermaniMaurizio C Capogrossi
Dec 11, 2008·Birth Defects Research. Part C, Embryo Today : Reviews·Amandine F G GodierGordana Vunjak-Novakovic
Mar 20, 2013·BioMed Research International·Calvin C ShengJijun Hao
Jan 31, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gianni AngeliniPaolo Madeddu
Jun 30, 2009·Cell Transplantation·Warren ShermanDaniel Burkhoff
Feb 28, 2006·Nature Clinical Practice. Cardiovascular Medicine·Warren ShermanTomasz Siminiak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Regeneration

Cardiac regeneration enables the repair of irreversibly damaged heart tissue using cutting-edge science, including stem cell and cell-free therapy. Discover the latest research on cardiac regeneration here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

Nature Clinical Practice. Cardiovascular Medicine
Philippe MenaschéAlbert A Hagège
The New England Journal of Medicine
Volker SchächingerREPAIR-AMI Investigators
The New England Journal of Medicine
Birgit AssmusAndreas M Zeiher
Proceedings of the National Academy of Sciences of the United States of America
Bertrand LeobonSerge Charpak
© 2021 Meta ULC. All rights reserved